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Background-—In 2011, the Brain Attack Coalition proposed door-to-treatment times of 2 hours as a benchmark for patients
undergoing intra-arterial therapy (IAT). We designed the Rapid Reperfusion Registry to capture the percentage of stroke patients
who meet the target and its impact on outcomes.
Methods and Results-—This is a retrospective analysis of anterior circulation patients treated with IAT within 9 hours of symptom
onset. Data was collected from December 31, 2011 to December 31, 2012 at 2 centers and from July 1, 2012 to December 31,
2012 at 7 centers. Short “Door-to-Puncture” (D2P) time was hypothesized to be associated with good patient outcomes. A total of
478 patients with a mean age of 6814 years and median National Institutes of Health Stroke Scale (NIHSS) of 18 (IQR 14 to 21)
were analyzed. The median times for IAT delivery were 234 minutes (IQR 163 to 304) for “last known normal-to-groin puncture”
time (LKN-to-GP) and 112 minutes (IQR 68 to 176) for D2P time. The overall good outcome rate was 39.7% for the entire cohort. In
a multivariable model adjusting for age, NIHSS, hypertension, diabetes, reperfusion status, and symptomatic hemorrhage, both
short LKN-to-GP (OR 0.996; 95% CI [0.993 to 0.998]; P<0.001) and short D2P times (OR 0.993, 95% CI [0.990 to 0.996]; P<0.001)
were associated with good outcomes. Only 52% of all patients in the registry achieved the targeted D2P time of 2 hours.
Conclusions-—The time interval of D2P presents a clinically relevant time frame by which system processes can be targeted
to streamline the delivery of IAT care nationally. At present, there is much opportunity to enhance outcomes through reducing
D2P. (J Am Heart Assoc. 2014;3:e000859 doi: 10.1161/JAHA.114.000859)
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h
e NCDR CathPCI registry was ﬁrst implemented in 1998
as a central repository for capturing real-life data on
patient proﬁles, clinical outcomes, and system processes
associated with percutaneous coronary intervention (PCI).
1
Beginning with <200 participating centers in 1999, the
registry has grown to include >1500 US hospitals and >12
million patient records by 2012.
2 Results from the CathPCI
registry have subsequently been used to demonstrate the
importance of “Door-to-Balloon” (D2B) times on patient
mortality,
3 while spearheading quality assurance initiatives
aimed at enhancing the delivery of PCI care. Between 2005
and 2008, the number of hospitals in the registry that
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ORIGINAL RESEARCHachieved D2B times of <90 minutes increased from 52% to
76%,
4 reﬂecting successful implementation of the best
practices associated with systems of care for STEMI patients.
Although multicenter registries have already been reported
for endovascular therapies (IAT) in stroke
5–7 the focus has
been predicated on the intra-procedural aspects of treatment
rather than the pre-procedural processes. A recent study
demonstrated that >three-quarters of the delays to reperfu-
sion are comprised of inefﬁciencies preceding the procedure
itself, which correlate with poorer outcomes following IAT.
8
Unfortunately, data capture of system processes prior to IAT
have yet to be standardized, thereby limiting the ability of
hospitals and institutions to deﬁne bottlenecks in times to
treatment.
To address these issues, we developed the Rapid Reper-
fusion Registry as a tool for collating multicenter data on
patients treated with IAT, with the goal of standardizing data
collection as well as providing a real-time assessment on the
pre-procedural metrics of “last known normal-to-puncture”
and “Door-to-Puncture” (D2P). We hypothesized that both
time intervals would not only be associated with patient
mortality and outcomes, but would also provide a standard-
ized template for future data collection from which bottle-
necks may be identiﬁed. The results from this study have
subsequently set the foundation for the second phase of
the registry, in which segmentation of D2P times will be
prospectively collected following the implementation of
evidence-based strategies aimed at reducing treatment times,
and ultimately, improving patient outcomes.
Methods
IRB approval was granted at Emory University to initiate a
multicenter registry to capture system processes associated
with endovascular therapy for ischemic stroke patients. Each
contributing hospital obtained local IRB approval to submit
their de-identiﬁed patient information on a pre-set template,
which was collected and stored at the coordinating center
(Grady Memorial Hospital). All acute ischemic stroke patients
(AIS) treated with IAT between June 31, 2012 to December
31, 2012 were retrospectively reviewed and considered for
inclusion in the analysis. Two institutions provided patient
records over a 12-month period between December 31, 2011
to December 31, 2012 (Grady Memorial Hospital and Vall
d’Hebron Hospital).
Data Collection
Data pertaining to baseline characteristics (ie, age, gender,
hypertension, diabetes mellitus, atrial ﬁbrillation), initial
stroke severity (NIHSS), prior IV-tPA delivery, and clot location
on angiography were collected in the registry. Signiﬁcant
time points in the work-up of acute stroke patients were
documented including: last known normal, arrival to ﬁrst
hospital, time of arterial access, time of reperfusion success,
and in certain cases, time of initial CT imaging. Door-to-
Puncture times were calculated as the interval between ﬁrst
hospital admission and arterial access, irrespective of transfer
status. When possible, all pretreatment CT images were
evaluated for the Alberta Stroke Program Early CT score as a
surrogate for pretreatment infarct size.
9 Symptomatic hem-
orrhages (sICH) were deﬁned according to the ECASS
deﬁnition as parenchymal hematomas type I or type II found
of postprocedural CT images within 24 hours of treatment.
10
Deterioration of NIHSS scores could not be accurately
documented given the retrospective nature of the study,
and thus, were excluded from the sICH deﬁnition. Successful
reperfusion was classiﬁed as Thrombolysis in Cerebral
Infarction (TICI) scores of 2b or greater on immediate
angiographic imaging, which correlates to partial or complete
reperfusions of the vascular territory involved.
Outcome Measures
The primary endpoint of “good outcomes” was deﬁned as a
modiﬁed Rankin Scale score of 0 to 2 at 9014 days, which
was determined by follow-up exams or phone interviews
conducted by certiﬁed examiners blinded to the treatment
times. The secondary endpoint of all-cause mortality at
90 days was also obtained during this time.
All data pertaining to pretreatment imaging, reperfusion
success, postoperative hemorrhages, and 90-day outcomes
were locally adjudicated at each center, with time metrics
captured based on the ofﬁcial time stamps from each
patient’s electronic medical record.
Patient Selection
All consecutive patients treated with endovascular therapy
were included with large-vessel occlusions involving the
anterior circulation (ie, ICA-T/M1/M2) and treatment within
9 hours of last known normal.
Statistical Analysis
Baseline patient characteristics were compared between all
contributing centers in the Rapid Reperfusion Registry. A
univariate analysis was performed to determine the variables
associated with favorable outcomes at 90 days. Each inde-
pendent predictor with P<0.10 was subsequently adjusted in
a binary logistic regression model, with odds ratios and 95%
conﬁdence intervals reported. The goodness-of-ﬁt of the
model was conﬁrmed by Hosmer-Lemeshow testing. “LKN-to-
GP” times were subsequently quintiled to determine the
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The lowest quintile was used as the reference point for
comparison with the latter time groups. A separate binary
logistic regression model was also generated to determine the
relationship between good outcomes and a narrower metric of
D2P. All analyses were performed using IBM SPSS v.20.
Results
A total of 629 patients met inclusion criteria of which 75
(12%) did not have documented groin puncture times and 76
(12%) did not have a 90-day mRS. Thus, a total of 478 (76%)
patients were analyzed. The mean age and median NIHSS
score for the entire cohort was 68.214.2 and 18 (IQR 14 to
21), respectively. Overall, 320 patients (68%) had successful
reperfusion, 268 patients (56%) received IV t-PA prior to IAT,
and 58 patients (12.4%) developed parenchymal hematomas
post procedure. The median times for IAT delivery corre-
sponded to an LKN-to-GP time of 234 minutes (IQR 163 to
304) and a D2P time of 112 minutes (IQR 68 to 176). At
3 months, all-cause mortality was reported in 111 patients
(27.2%), while good outcomes were observed in 234 patients
(39.7%). The differences in patient characteristics between
the study centers are described in Table 1.
LKN-to-GP and Patient Outcomes
In a binary logistic regression model adjusting for age, NIHSS,
hypertension, diabetes mellitus, IV t-PA delivery, reperfusion
status, and symptomatic hemorrhage, the pre-procedural time
frame of LKN-to-GP was directly associated with 90-day good
outcomes (OR 0.996; 95% CI [0.993 to 0.998]; P<0.001)
(Table 2). This relationship also held true in a secondary
model adjusting for pretreatment ASPECTS (OR 0.996; 95% CI
[0.994 to 0.999]; P=0.003). As shown in Figure 1, 53% of the
patients had a good outcome when treated within 150 min-
utes from LKN, which declined to 39% at 208 to 259 minutes
and 27% at 330 minutes or greater. The odds ratio for a good
outcome declined at each interval beyond the reference point
(LKN-to-GP<150 minutes) with signiﬁcance achieved beyond
260 minutes: LKN-to-GP 260 to 329 minutes: (OR 0.43; 95%
CI [0.20 to 0.89]; P=0.023; LKN-to-GP ≥330 minutes: (OR
0.30; 95% CI [0.14 to 0.65]; P=0.002).
Door-to-GP and Patient Outcomes
The direct relationship between time and patient outcomes
was also noted for D2P. As shown in Figure 2, the probability
for a good outcome declined at each subsequent interval from
the initial reference group of “D2P<60 minutes.” Of note,
the odds for good outcomes signiﬁcantly decreased to 0.40
(95% CI 0.17 to 0.93; P=0.034) and 0.17 (95% CI 0.07 to
0.43; P<0.001) at “D2P” intervals of 136 to 205 minutes
and ≥206 minutes, respectively (Table 3). This relationship
between “D2P” times and outcome rates remained signiﬁcant
in all models, either adjusting for ASPECTS (Model 2: OR
0.995, 95% [0.991 to 0.999]; P=0.012), adjusting without
ASPECTS (Model 1: OR 0.993, 95% CI [0.990 to 0.996];
P<0.001), or including “site” as an independent predictor
(Table 4: OR 0.994, 95% CI [0.990 to 0.998]; P=0.007). In
total, only 211 patients (52%) met the AHA guideline of arrival-
to-treatment within 2 hours.
In a secondary analysis, imputation of “poor outcomes” (ie,
mRS=6) was applied to all patients with missing 90-day mRS
scores (n=76) and adjusted accordingly to Model 1. In this
scenario, both “LKN-to-GP” (OR 0.996; 95% CI 0.994 to
0.998; P<0.001) and “Door-to-Puncture” times (OR 0.993;
95% CI 0.990 to 0.996; P<0.001) remained independently
associated with poor patient outcomes for every minute delay
to puncture, thereby supporting the results of the initial
models.
“D2P” times were also associated with all-cause mortality
at 90 days (OR 1.004; 95% CI [1.001 to 1.007]; P=0.018)
when correcting for age, NIHSS, hypertension, diabetes
mellitus, reperfusion status, and hemorrhage rates. Patients
presenting within 60 minutes of “D2P” had a 24.7% all-cause
mortality rate (reference), as compared with 31.7% (OR 1.70,
95% CI [0.69 to 4.2]; P=0.24) and 39.2% (OR 2.80, 95% CI
[1.16 to 6.74]; P=0.022) at intervals of 136 to 205 minutes
and ≥206 minutes, respectively.
Discussion
Performance metrics for standardizing data collection involv-
ing IAT at Comprehensive Stroke Centers have previously
been described in several consensus statements
11,12 and
retrospective studies.
8,13 As recently as 2011, the AHA
proposed the use of an “Arrival-to-Treatment” metric of
<2 hours for all endovascular interventions. Real world data,
however, has yet to provide clinical signiﬁcance for the
implementation of this metric and its corresponding par-
ameters.
More recently, the term “onset-to-reperfusion time” (ORT)
has been proposed as an ideal marker for performance, in
which shorter ORTs directly correlate with improved patient
outcomes and lower mortality rates at 90 days.
14 Although
this metric may hold the most physiological relevance with
regard to ischemic burden, certain variables within the overall
time frame may be difﬁcult to modify at an institutional level.
For example, the time from onset-to-hospital arrival is
contingent on patient awareness of stroke symptoms and
the infrastructure of EMS transportation to CSCs. Conversely,
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Study Site 1 Study Site 2 Study Site 3 Study Site 4 Study Site 5 Study Site 6 Other Sites (7 to 9)
Recruitment Period
Dec 2012–Dec
2013
Dec 2012–Dec
2013
July 2013–Dec
2013
July 2013–Dec
2013
July 2013–Dec
2013
July 2013–Dec
2013
July 2013–Dec
2013
Demographics
Number of patients n=164 n=142 n=91 n=27 n=20 n=15 n=19
Age, mean (STD) 70.6 (13.5) 65.6 (15.0) 67.6 (13.4) 67.2 (15.3) 71.2 (11.6) 62.3 (15.5) 70.5 (14.0)
Male gender, no. (%) 81 (49) 76 (54) 45 (50) 13 (48) 12 (60) 3 (20) 9 (47)
Hypertension, no. (%) 105 (64) 108 (76) 45 (50) 20 (74) 13 (65) 10 (67) 14 (74)
Atrial fibrillation, no. (%) 69 (42) 54 (38) 29 (32) 14 (52) 9 (45) 3 (20) 8 (42)
Diabetes, no. (%) 32 (20) 40 (28) 15 (16) 5 (19) 4 (20) 6 (40) 6 (32)
Neurological severity
Pre-treatment NIHSS,
median (IQR)
18.5 (17 to 21) 18 (14 to 23) 17 (13 to 21) 14 (11 to 18) 16 (14 to 18) 19 (16 to 23) 19 (15 to 22)
IV tPA given, no. (%) 101 (62) 79 (56) 48 (53) 10 (37) 11 (55) 7 (47) 12 (63)
Radiographic assessment
ASPECTS,
median (IQR) *
10 (9 to 10) 8 (7 to 9) 8 (7 to 9) 9 (7 to 10) N/A N/A 8 (6 to 9)
Multimodal imaging,
no. (%)
†
38 (47) 78 (55) 91 (100) 16 (59) 20 (100) 14 (93) 19 (100)
Clot location
ICA, no (%) 61 (37) 29 (20) 24 (26) 7 (26) 6 (30) 4 (27) 9 (47)
MCA, no (%) 103 (63) 113 (80) 67 (74) 20 (74) 14 (70) 11 (73) 10 (53)
Successful
reperfusion,
no. (%)
‡
77 (49) 111 (79) 74 (81) 24 (89) 12 (60) 11 (73) 11 (58)
PH1/PH2
hemorrhage,
no. (%)
18 (11) 9 (6) 16 (17) 6 (22) 2 (10) 2 (13) 5 (26)
Time metrics (in minutes)
LKN-to-GP,
median (IQR)
210 (150 to 270) 261 (195 to 340) 177 (124 to 254) 290 (250 to 354) 288 (209 to 328) 330 (193 to 422) 266 (230 to 350)
Door-to-GP,
median (IQR)
75 (50 to 128) 164 (129 to 233) 84 (59 to 104) 90 (37 to 120) 259 (213 to 311) 214 (105 to 251) 200 (146 to 221)
Procedure time,
median (IQR)
83 (54 to 131) 64 (41 to 95) 43 (27 to 75) 56 (41 to 68) 69 (51 to 96) 57 (40 to 67) 84 (71 to 150)
Transfer from
PSC, no. (%)
§
56 (37) 98 (69) 0 (0) N/A 12 (60) 10 (67) 13 (68)
Outcome measures
90-day mortality
rate, no. (%)
52 (32) 37 (26) 20 (22) 8 (30) 5 (25) 2 (13) 6 (32)
Good outcomes,
no. (%)
57 (35) 51 (36) 54 (59) 12 (44) 6 (30) 6 (40) 4 (21)
Acceptable
outcomes,
no. (%)
74 (45) 66 (46) 62 (68) 15 (56) 8 (40) 8 (53) 6 (32)
ASPECTS indicates Alberta Stroke Program Early CT Score; GP, groin puncture; ICA, internal carotid artery; IQR, interquartile range; LKN, last known normal; MCA, middle cerebral artery;
NIHSS, NIH Stroke Scale; PH, parenchymal hematoma; PSC, primary stroke center; t-PA, tissue plasminogen activator.
*ASPECTS scores were not evaluated at Sites 5 and 6.
†Multimodal imaging status was not available for every patient at Site 1.
‡Reperfusion status was not available for every patient at Site 1.
§PSC transfer data was not available at Site 4.
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personnel in the angiosuite, the types of devices used during
the operation, and the interpretation of reperfusion status, all
of which are more difﬁcult to homogenize in establishing
standards. As such, the AHA-proposed “Arrival-to-Treatment”
time (which we deﬁne as “Door-to-Puncture”) may present a
more “actionable” time frame by which strategies can be
implemented at an institutional level to effect change.
In this report, we present preliminary data from the
multicenter Rapid Reperfusion Registry that demonstrates the
clinical signiﬁcance of “D2P” times on patient outcomes, as
well as establishes a benchmark for the current status of D2P
times from 9 separate institutions. In particular, our data
reveal that patients treated within 1 hour from ﬁrst hospital
arrival have the highest odds ratio for a good outcome,
regardless of transfer status, which subsequently declines by
7% for every 10-minute delay to treatment. This relationship
similarly holds true when evaluating the broader metric of
“LKN-to-puncture,” in which every 30-minute delay to treat-
ment from last known normal corresponds to a 12% reduction
in the odds of a good outcome. This is consistent with the
results from a previously published multicenter analysis.
14
Regardless of the metric used, the timing to IAT delivery
remains an important denominator to consider in light of the
recent nonpositive trial results comparing IAT with medical
therapy.
15–17 Between 1999 and 2013, reperfusion rates and
procedure times continued to improve with advancements in
device technology,
18–21 yet the timing from “LKN-to-treat-
ment” has not substantially decreased from the initial 4- to
5-hour time window described in PROACT II.
22 From the
current dataset of patients treated in 2012, the median
time from “LKN-to-GP” remains at 4 hours (234 minutes),
whereas the median time from “D2P” was nearly 2 hours
(112 minutes), reiterating the notion that system processes
in IAT have yet to improve in conjunction with device
technologies.
Table 2. Patient Outcomes Stratiﬁed by LKN-to-Puncture
LKN-to-
Puncture
Good Outcome/
Total
%Good
Outcome
Unadjusted Odds Ratio for Good
Outcome
Adjusted Odds Ratio for Good Outcome*
(Model 1)
Adjusted Odds Ratio for Good Outcome
†
(Model 2)
<150 minutes 49/92 53.3 Reference Reference Reference
150 to 207
minutes
48/99 48.5 0.83 (0.47 to 1.46);
P=0.51
0.96 (0.46 to 1.97);
P=0.90
1.02 (0.47 to 2.19);
P=0.97
208 to 259
minutes
37/95 38.9 0.56 (0.31 to 1.00);
P=0.05
0.83 (0.40 to 1.72);
P=0.61
0.83 (0.38 to 1.81);
P=0.64
260 to 329
minutes
30/95 31.6 0.41 (0.22 to 0.74);
P=0.003
0.43 (0.20 to 0.89);
P=0.023
0.53 (0.24 to 1.17);
P=0.12
≥330
minutes
26/97 26.8 0.32 (0.18 to 0.59);
P<0.001
0.30 (0.14 to 0.65);
P=0.002
0.31 (0.13 to 0.74);
P=0.008
All 190/478 39.7 0.996 (0.994 to 0.998);
P<0.001
0.996 (0.993 to 0.998);
P<0.001
0.996 (0.994 to 0.999);
P=0.003
ASPECTS indicates Alberta Stroke Program Early CT Score; LKN, last known normal; NIHSS, NIH Stroke Scale; tPA, tissue plasminogen activator.
*Model 1: Corrected for age, NIHSS, hypertension, diabetes, IV tPA delivery, reperfusion status, and symptomatic hemorrhage.
†Model 2: Corrected for age, NIHSS, hypertension, diabetes, IV tPA delivery, reperfusion status, symptomatic hemorrhage, and ASPECTS scores (excluding Sites 5 and 6).
Figure 1. Association between LKN-to-GP and good outcomes.
GP indicates groin puncture; LKN, last known normal; OR, odds
ratio; Hosmer Lemeshow test conﬁrms good-of-ﬁt of the model
(P>0.05).
Figure 2. Association between door-to-puncture and good
outcomes. GP indicates groin puncture; LKN, last known normal;
OR, odds ratio; Hosmer-Lemeshow test conﬁrms good-of-ﬁt of the
model (P>0.05).
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puncture time of 208 minutes, with an average NIHSS of 17
and overall good outcome rate of 40.8%. Our dataset reveals a
similar result, with an average “LKN-to-GP” of 234 minutes,
median NIHSS of 18, and an overall good outcome rate of
39.7%. When comparing our registry data to the IV tPA arm in
IMS III, which had an onset-to-treatment time of 121 minutes,
the net difference in percent good outcomes was insigniﬁcant
(RRR: 39.7% versus IMS III: 38.7%). However, if the IAT curve
can be reduced by 60 minutes and shifted closer to the
3-hour mark (ie, LKN-to-GP 150 to 207 minutes; NIHSS 19),
as observed in the second quintile of our dataset, the overall
good outcome rate approaches 48.5%. This would establish an
absolute difference of 10% when compared to the IV tPA
group in IMS III, which was the estimated difference in
powering the original study (Table 5; Figure 3).
The current study suggests that any effort to improve the
treatment efﬁcacy of IAT must begin with reductions in “LKN-
to-GP” times. This may be achieved by targeting the
“actionable” time frame of D2P. Strategies including: direct
activation of the IR lab by the ED physician; selection of
patients for IAT without multimodal imaging (ie, ASPECTS
scoring; thin-cut reconstruction); and applying distance
thresholds for inter-facility transfers have all been previously
described as measures to reduce the delays associated with
IAT.
8 It is also notable in the current registry that the target
D2P of <2 hours, as proposed by the AHA, was achieved in
only 52% of the patients. Indeed, this is a signiﬁcant obstacle
to any study evaluating the efﬁcacy of IAT, as delays to
treatment will always diminish the anticipated effect size of
IAT. The AHA’s proposal of 2 hours from “arrival-to-treat-
ment” reﬂects more of an infrastructural limitation on the
ability of hospitals to achieve IAT within 2 hours, rather than
ad e ﬁnitive therapeutic beneﬁt. As our data suggest,
treatment with IAT at even earlier time points of <60 minutes
may provide the greatest therapeutic beneﬁt for patients
undergoing endovascular therapies. The fact that only half of
the patients in our registry were treated within 120 minutes
highlights the importance for centers to improve their current
performance standards and to implement new strategies for
Table 3. Patient Outcomes Stratiﬁed by Door-to-Puncture
Door-to-
Puncture
Good
Outcome/Total
%Good
Outcome
Unadjusted Odds Ratio for Good
Outcome
Adjusted Odds Ratio for Good
Outcome* (Model 1)
Adjusted Odds Ratio for Good
Outcome
† (Model 2)
<60 minutes 36/77 46.8 Reference Reference Reference
60 to
90 minutes
41/85 48.2 1.06 (0.57 to 1.97); P=0.85 0.83 (0.37 to 1.85); P=0.64 0.72 (0.31 to 1.66); P=0.44
91 to
135 minutes
44/83 53.0 1.28 (0.69 to 2.39); P=0.43 0.65 (0.28 to 1.50); P=0.32 0.64 (0.27 to 1.53); P=0.32
136 to
205 minutes
27/82 33.0 0.56 (0.29 to 1.06); P=0.076 0.40 (0.17 to 0.93); P=0.034 0.47 (0.19 to 1.21); P=0.12
≥206 minutes 16/79 20.2 0.29 (0.14 to 0.59); P=0.001 0.17 (0.07 to 0.43); P<0.001 0.24 (0.09 to 0.67); P=0.006
All (per
minute)
164/406
‡ 40.4 0.995 (0.992 to 0.997); P<0.001 0.993 (0.990 to 0.996); P<0.001 0.995 (0.991 to 0.999); P=0.012
*Model 1: Corrected for age, NIHSS, hypertension, diabetes, IV tPA delivery, reperfusion status, and symptomatic hemorrhage.
†Model 2: Corrected for age, NIHSS, hypertension, diabetes, IV tPA delivery, reperfusion status, symptomatic hemorrhage, and ASPECTS scores (excluding Sites 5 and 6).
‡Door-to-Puncture times were not available for 72 patients. ASPECTS indicates Alberta Stroke Program Early CT Score; NIHSS, NIH Stroke Scale; tPA, tissue plasminogen
activator.
Table 4. Binary Logistic Regression Model Identifying
Variables Associated With Good Outcome After Intra-arterial
Therapy for Acute Ischemic Stroke
Variable OR (95% CI) P Value
Age 0.96 (0.94 to 0.98) <0.001
Hypertension 0.69 (0.38 to 1.23) 0.229
NIHSS 0.84 (0.79 to 0.89) <0.001
Diabetes 0.66 (0.33 to 1.30) 0.225
IV tPA given 1.68 (0.98 to 2.89) 0.062
Successful reperfusion 9.33 (4.69 to 18.57) <0.001
Symptomatic hemorrhage 0.40 (0.16 to 1.03) 0.059
Door-to-puncture (min) 0.994 (0.990 to 0.998) 0.007
Site no. Site 1 (reference) 0.460
Site 2 0.68 (0.32 to 1.47) 0.329
Site 3 1.42 (0.65 to 3.08) 0.377
Site 4 0.35 (0.10 to 1.20) 0.095
Site 5 0.60 (0.12 to 2.95) 0.524
Site 6 0.70 (0.09 to 5.59) 0.735
Other sites 0.53 (0.06 to 4.58) 0.560
CI indicates conﬁdence interval; NIHSS, NIH Stroke Scale; OR, odds ratio; Homser-
Lemeshow test depicts goodness of ﬁt to the model (P>0.05); t-PA, tissue plasminogen
activator.
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been initiated in a study by Mehta et al, in which strategies
for parallel processing and lean modeling have substantially
reduced the delays from “door-to-puncture” by 36 minutes at
a single center (B. Mehta, MD, et al, unpublished data,
2014). To our knowledge, this database is also the ﬁrst
pooled analysis of IAT treatment times to control for
pretreatment ASPECTS as a potential confounder for initial
stroke severity.
This current analysis has several limitations. First, we did
not collate data on the intra-procedural processes associated
with endovascular reperfusion, and thus, cannot comment on
its impact on patient outcomes. The type of thrombectomy
device used, the number of passes attempted, the presence
of adjuvant therapy, and the choice of anesthesia
6,24,25 are all
variables that cannot be presently accounted for, although the
technologies employed are all from the post-Merci retriever
era. Nevertheless, our goal was to focus primarily on the pre-
procedural components of patient care, and to model our
analysis after the successful “Door-to-Balloon” studies in
cardiology, which emphasized the importance of times to
catheterization rather than device strategy.
26
Second, given the retrospective nature of the study, only
85% of the patients had documented “Door-to-Puncture”
times, and thus, conclusions may not be applicable to all
consecutive patients. Among the patients who received IV
tPA, our current dataset cannot distinguish between those
who received t-PA in a “drip-and-ship” model versus those
who received t-PA at the CSC. In addition, the utilization of
imaging parameters in the decision-making for IAT (ie,
baseline ASPECTS and/or multimodal imaging) was not
standardized across all contributing centers, which adds to
the level of heterogeneity. For example, at Study Site 5, all
patients undergoing IAT were required to undergo multimodal
imaging prior to intervention, whereas at Study Site 2, such
imaging was only utilized in 55% of the patients.
Lastly, the Rapid Reperfusion Registry was designed as
only an observational study. Deﬁnitive conclusions regarding
the impact of time on outcomes cannot be proven without
randomizing patients in a case-control fashion to a “fast
treated” group versus a “slow treated” group. The results from
the study are also only reﬂective of the 9 contributing
hospitals, and thus, are not representative of all Comprehen-
sive Stroke Centers on a national level.
Nevertheless, our study demonstrates the importance of
pre-procedural treatment times in association with patient
outcomes, as observed from a multicenter perspective. Our
results have subsequently set the stage for the second phase
of our registry, which will be designed to prospectively collect
data pertaining to the interval processes involved in the work-
up of acute stroke patients designated for endovascular
intervention. Time points including: initial EMS contact in
the ﬁeld; arrival to PSC/CSC; initial CT imaging; time of
multimodal imaging; time of neurology consultation; time of
tPA delivery; initial contact with neurointerventionists; accep-
tance to treatment facilities; and EMS transfer times for inter-
facility transfers will all be documented in a prospective
manner. This will then allow us to provide granular detail
regarding the system processes associated with delays to IAT,
and thus, provide a framework by which strategies can be
applied to minimize treatment times. These strategies will
Figure 3. The impact of time on patients outcomes: RRR vs
previous IAT/IV-tPA studies. Median NIHSS in lancet analysis
23
for <90 minutes group was 11. All other study groups depicted in
the ﬁgure had a median NIHSS of 16 to 19. IAT indicates intra-
arterial therapy; IMS, Interventional Management of Stroke III
trial; LKN, last known normal; NIHSS, NIH Stroke Scale; RRR,
Rapid Reperfusion Registry; t-PA, tissue plasminogen activator.
Table 5. Comparison of Patient Outcomes in the RRR
Database Versus Previously Published IAT and IV-tPA
Randomized Controlled Studies
Study Group
LKN-to-Treatment,
Mean Minutes
(STD)
% Good
Outcome
Rate
Median
NIHSS
RRR: IAT
<150 minutes
108 (28) 53.5 17
RRR: IAT 150 to
207 minutes
178 (18) 48.5 19
RRR: IAT 208 to
259 minutes
231 (16) 38.9 18
RRR: IAT 260 to
329 minutes
290 (19) 31.6 18
RRR: IAT
≥330 minutes
411 (63) 26.8 17
IMS III: IV tPA arm
15 121 (34) 38.7 16
IMS III: IAT arm
15 208 (47) 40.8 17
Lancet 2010: IV tPA
pooled, <90 minutes
group
23
90 (N/A) 48 11
IAT indicates intra-arterial therapy; IMS, Interventional Management of Stroke; LKN, last
known normal; N/A, not available; NIHSS, NIH Stroke Scale; RRR, Rapid Reperfusion
Registry; t-PA, tissue plasminogen activator.
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improving patient outcomes in endovascular therapy for
stroke.
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